NCT01594957View on ClinicalTrials.gov

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Hepatic Impairment
Interventions
DRUG

LCQ908

Participants will receive a single oral dose of LCQ908

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

33136

Novartis Investigative Site, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY